Chronic Kidney Disease (CKD) is a widespread and frequently under recognised condition impacting millions around the globe. With an ageing population, the prevalence of CKD is projected to rise ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Discover scPharmaceuticals' Q4 2024 achievements, including FUROSCIX's CKD approval, Medicare redesign insights, and strategies for 2025 growth.

Clinicians should continue to monitor UACR or UPCR in at-risk children. During periods of rapid growth such as puberty, children with low GFR may show rapid decline in kidney function. Puberty is a ...

Uganda has made significant strides in kidney care, including the establishment of dialysis centres and successful kidney ...

Akebia Therapeutics, Inc.’s AKBA share price has dipped by 22.21%, which has investors questioning if this is right time to ...

The number of end-stage kidney disease patients undergoing chronic dialysis could double to more than 106,000 patients by ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 millionCash and cash ...

When your kidneys can no longer function properly, renal replacement therapy (RRT) becomes a lifesaving option. Whether ...

The market has been harsh on most growth stocks this year, owing primarily to tariff-related recession fears. In a volatile ...

According to the CDC, around 37 million American adults have chronic kidney disease, and millions more are at risk of developing it.

Dialysis Centers used data from the Centers for Disease Control and Prevention to examine the prevalence of chronic diseases ...